 Jonathan Gutman
Concepts (308)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cord Blood Stem Cell Transplantation | 19 | 2023 | 91 | 5.470 |
Why?
| | Leukemia, Myeloid, Acute | 24 | 2024 | 533 | 5.150 |
Why?
| | Hematopoietic Stem Cell Transplantation | 19 | 2023 | 519 | 5.100 |
Why?
| | Graft vs Host Disease | 14 | 2023 | 212 | 4.160 |
Why?
| | Transplantation Conditioning | 15 | 2023 | 149 | 2.600 |
Why?
| | Azacitidine | 10 | 2024 | 129 | 2.500 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 12 | 2024 | 172 | 2.020 |
Why?
| | Sulfonamides | 11 | 2024 | 444 | 1.590 |
Why?
| | Hematologic Neoplasms | 6 | 2021 | 136 | 1.350 |
Why?
| | Myelodysplastic Syndromes | 5 | 2019 | 119 | 0.880 |
Why?
| | Fetal Blood | 6 | 2022 | 268 | 0.870 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 10 | 0.870 |
Why?
| | Cytomegalovirus Infections | 3 | 2023 | 180 | 0.840 |
Why?
| | Recurrence | 10 | 2023 | 925 | 0.790 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 1356 | 0.720 |
Why?
| | Neoplasm, Residual | 5 | 2024 | 104 | 0.680 |
Why?
| | Leukemia | 5 | 2011 | 208 | 0.670 |
Why?
| | Pregnancy Complications | 1 | 2023 | 430 | 0.630 |
Why?
| | Clostridium Infections | 1 | 2019 | 54 | 0.620 |
Why?
| | Transplantation, Homologous | 11 | 2023 | 377 | 0.620 |
Why?
| | Vancomycin | 1 | 2019 | 75 | 0.610 |
Why?
| | Thiotepa | 1 | 2018 | 19 | 0.610 |
Why?
| | Humans | 69 | 2024 | 114080 | 0.530 |
Why?
| | Antineoplastic Agents | 6 | 2020 | 1875 | 0.530 |
Why?
| | Retrospective Studies | 14 | 2024 | 12521 | 0.510 |
Why?
| | Adult | 34 | 2024 | 30395 | 0.490 |
Why?
| | Stem Cell Transplantation | 4 | 2023 | 148 | 0.450 |
Why?
| | Carbon Monoxide | 1 | 2013 | 64 | 0.410 |
Why?
| | Middle Aged | 31 | 2024 | 26621 | 0.410 |
Why?
| | Blood Banks | 2 | 2012 | 38 | 0.400 |
Why?
| | Aged | 22 | 2024 | 18973 | 0.390 |
Why?
| | Hematopoietic Stem Cells | 3 | 2015 | 338 | 0.390 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2012 | 14 | 0.390 |
Why?
| | Blood Specimen Collection | 1 | 2011 | 31 | 0.380 |
Why?
| | HLA Antigens | 4 | 2019 | 220 | 0.370 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2017 | 193 | 0.360 |
Why?
| | Germ-Line Mutation | 1 | 2012 | 131 | 0.360 |
Why?
| | Hemoglobins | 1 | 2013 | 308 | 0.360 |
Why?
| | Lymphoma | 2 | 2017 | 176 | 0.360 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1472 | 0.340 |
Why?
| | Whole-Body Irradiation | 5 | 2019 | 72 | 0.340 |
Why?
| | Cesarean Section | 1 | 2011 | 169 | 0.340 |
Why?
| | Graft vs Leukemia Effect | 1 | 2009 | 12 | 0.330 |
Why?
| | Female | 36 | 2024 | 59349 | 0.330 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2023 | 850 | 0.330 |
Why?
| | Neoplastic Stem Cells | 3 | 2018 | 327 | 0.320 |
Why?
| | Pulmonary Veno-Occlusive Disease | 1 | 2008 | 11 | 0.310 |
Why?
| | Isoantibodies | 1 | 2009 | 52 | 0.310 |
Why?
| | Disease-Free Survival | 4 | 2022 | 618 | 0.290 |
Why?
| | Rhinovirus | 1 | 2007 | 40 | 0.290 |
Why?
| | Picornaviridae Infections | 1 | 2007 | 29 | 0.280 |
Why?
| | Graft Rejection | 2 | 2012 | 511 | 0.280 |
Why?
| | Male | 36 | 2024 | 55420 | 0.280 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2013 | 94 | 0.280 |
Why?
| | Young Adult | 11 | 2021 | 10459 | 0.280 |
Why?
| | Vidarabine | 2 | 2018 | 26 | 0.260 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2020 | 637 | 0.260 |
Why?
| | Clonal Evolution | 2 | 2017 | 25 | 0.260 |
Why?
| | Altitude Sickness | 4 | 2008 | 170 | 0.250 |
Why?
| | Chronic Disease | 3 | 2022 | 1579 | 0.240 |
Why?
| | Mutation | 3 | 2024 | 3338 | 0.240 |
Why?
| | Histocompatibility Testing | 3 | 2016 | 115 | 0.230 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2009 | 687 | 0.230 |
Why?
| | Altitude | 5 | 2007 | 435 | 0.220 |
Why?
| | Treatment Outcome | 11 | 2024 | 9051 | 0.220 |
Why?
| | Prognosis | 6 | 2024 | 3315 | 0.220 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 320 | 0.220 |
Why?
| | Immune Reconstitution | 1 | 2023 | 6 | 0.220 |
Why?
| | Living Donors | 1 | 2005 | 270 | 0.210 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2017 | 660 | 0.210 |
Why?
| | Unrelated Donors | 3 | 2021 | 37 | 0.200 |
Why?
| | Pulmonary Edema | 3 | 2007 | 109 | 0.200 |
Why?
| | Carrier Proteins | 2 | 2017 | 694 | 0.200 |
Why?
| | Nuclear Proteins | 2 | 2017 | 591 | 0.190 |
Why?
| | Siblings | 1 | 2022 | 220 | 0.180 |
Why?
| | Salvage Therapy | 2 | 2019 | 127 | 0.180 |
Why?
| | Chimerism | 1 | 2021 | 28 | 0.180 |
Why?
| | Allografts | 1 | 2021 | 121 | 0.180 |
Why?
| | Antibodies, Monoclonal | 2 | 2017 | 1257 | 0.180 |
Why?
| | Myeloablative Agonists | 2 | 2018 | 21 | 0.180 |
Why?
| | Stem Cells | 2 | 2015 | 541 | 0.180 |
Why?
| | Sirolimus | 2 | 2019 | 181 | 0.180 |
Why?
| | Quality of Life | 2 | 2022 | 2346 | 0.170 |
Why?
| | Survival Analysis | 3 | 2018 | 1206 | 0.170 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 175 | 0.170 |
Why?
| | Antiviral Agents | 3 | 2023 | 642 | 0.170 |
Why?
| | Leukocytes | 1 | 2021 | 272 | 0.170 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2019 | 17 | 0.160 |
Why?
| | Relaxation Therapy | 1 | 2019 | 15 | 0.160 |
Why?
| | Breathing Exercises | 1 | 2019 | 18 | 0.160 |
Why?
| | Fetus | 1 | 2023 | 698 | 0.160 |
Why?
| | Acetates | 1 | 2019 | 94 | 0.160 |
Why?
| | Busulfan | 2 | 2020 | 14 | 0.160 |
Why?
| | Adolescent | 10 | 2019 | 17811 | 0.160 |
Why?
| | Mycophenolic Acid | 1 | 2019 | 76 | 0.160 |
Why?
| | Cyclosporine | 1 | 2019 | 161 | 0.160 |
Why?
| | Mountaineering | 3 | 2008 | 45 | 0.150 |
Why?
| | Socioeconomic Factors | 1 | 2022 | 1080 | 0.150 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2013 | 256 | 0.150 |
Why?
| | Quinazolines | 1 | 2019 | 240 | 0.150 |
Why?
| | Psychotherapy | 1 | 2019 | 149 | 0.140 |
Why?
| | Optic Nerve | 2 | 2008 | 65 | 0.140 |
Why?
| | Intracranial Pressure | 2 | 2008 | 48 | 0.140 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 184 | 0.140 |
Why?
| | Leukemia, Neutrophilic, Chronic | 1 | 2017 | 5 | 0.140 |
Why?
| | Receptors, Colony-Stimulating Factor | 1 | 2017 | 5 | 0.140 |
Why?
| | Immunosuppressive Agents | 2 | 2019 | 641 | 0.140 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 32 | 0.140 |
Why?
| | Pregnancy | 2 | 2023 | 5503 | 0.140 |
Why?
| | Administration, Oral | 1 | 2019 | 725 | 0.140 |
Why?
| | Aged, 80 and over | 7 | 2024 | 6307 | 0.140 |
Why?
| | Myelin Sheath | 2 | 2008 | 138 | 0.130 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 48 | 0.130 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2016 | 71 | 0.130 |
Why?
| | Adipocytes, White | 1 | 2015 | 17 | 0.130 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 7 | 0.130 |
Why?
| | Leukocytosis | 1 | 2015 | 34 | 0.130 |
Why?
| | Gene Frequency | 1 | 2017 | 476 | 0.130 |
Why?
| | Hodgkin Disease | 1 | 2017 | 121 | 0.120 |
Why?
| | Pulmonary Diffusing Capacity | 2 | 2013 | 60 | 0.120 |
Why?
| | Computational Biology | 1 | 2019 | 528 | 0.120 |
Why?
| | Incidence | 3 | 2016 | 2314 | 0.120 |
Why?
| | Dalteparin | 1 | 2014 | 9 | 0.120 |
Why?
| | Respiratory Function Tests | 2 | 2013 | 522 | 0.110 |
Why?
| | Pyrazoles | 1 | 2017 | 361 | 0.110 |
Why?
| | Harringtonines | 1 | 2013 | 2 | 0.110 |
Why?
| | Neoplasms | 2 | 2019 | 2089 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 385 | 0.110 |
Why?
| | Transplantation Chimera | 2 | 2012 | 51 | 0.110 |
Why?
| | Pyridazines | 1 | 2013 | 46 | 0.100 |
Why?
| | Antilymphocyte Serum | 1 | 2012 | 60 | 0.100 |
Why?
| | Caregivers | 1 | 2019 | 714 | 0.100 |
Why?
| | Receptors, CCR5 | 1 | 2012 | 54 | 0.100 |
Why?
| | Thrombocytopenia | 1 | 2014 | 177 | 0.100 |
Why?
| | Bone Marrow | 3 | 2021 | 243 | 0.100 |
Why?
| | Remission Induction | 3 | 2019 | 233 | 0.100 |
Why?
| | Risk Factors | 3 | 2014 | 8612 | 0.100 |
Why?
| | Sequence Deletion | 1 | 2012 | 166 | 0.100 |
Why?
| | Imidazoles | 1 | 2013 | 203 | 0.100 |
Why?
| | Fibrinolytic Agents | 1 | 2014 | 231 | 0.100 |
Why?
| | Hematopoiesis | 2 | 2010 | 170 | 0.100 |
Why?
| | Adipose Tissue | 1 | 2015 | 545 | 0.100 |
Why?
| | Lung Diseases | 2 | 2011 | 690 | 0.100 |
Why?
| | Length of Stay | 1 | 2016 | 957 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 1 | 2014 | 613 | 0.100 |
Why?
| | Ganciclovir | 1 | 2011 | 48 | 0.090 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 295 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2019 | 944 | 0.090 |
Why?
| | Thrombosis | 1 | 2014 | 295 | 0.090 |
Why?
| | Pedigree | 1 | 2012 | 460 | 0.090 |
Why?
| | Immunologic Factors | 1 | 2012 | 217 | 0.090 |
Why?
| | Acute Disease | 2 | 2012 | 909 | 0.090 |
Why?
| | Neutrophils | 1 | 2015 | 1089 | 0.090 |
Why?
| | Blood Donors | 1 | 2011 | 84 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2016 | 960 | 0.090 |
Why?
| | Cell Differentiation | 3 | 2015 | 1696 | 0.090 |
Why?
| | Umbilical Cord | 1 | 2010 | 80 | 0.090 |
Why?
| | Leukocytes, Mononuclear | 1 | 2012 | 489 | 0.080 |
Why?
| | Polymerase Chain Reaction | 2 | 2024 | 990 | 0.080 |
Why?
| | Treatment Failure | 2 | 2009 | 330 | 0.080 |
Why?
| | Opportunistic Infections | 1 | 2009 | 43 | 0.080 |
Why?
| | Infant | 4 | 2014 | 7946 | 0.080 |
Why?
| | Mycosis Fungoides | 1 | 2009 | 60 | 0.080 |
Why?
| | Child, Preschool | 4 | 2014 | 9121 | 0.080 |
Why?
| | Comorbidity | 1 | 2013 | 1447 | 0.080 |
Why?
| | Prednisolone | 1 | 2008 | 75 | 0.080 |
Why?
| | Family | 1 | 2012 | 589 | 0.070 |
Why?
| | Child | 7 | 2014 | 18408 | 0.070 |
Why?
| | Nepal | 4 | 2008 | 19 | 0.070 |
Why?
| | Warfarin | 1 | 2008 | 136 | 0.070 |
Why?
| | Cell Proliferation | 1 | 2014 | 2173 | 0.070 |
Why?
| | Heparin | 1 | 2008 | 225 | 0.070 |
Why?
| | Monitoring, Physiologic | 1 | 2009 | 248 | 0.070 |
Why?
| | Follow-Up Studies | 5 | 2019 | 4392 | 0.070 |
Why?
| | Fatal Outcome | 1 | 2007 | 281 | 0.070 |
Why?
| | Algorithms | 3 | 2009 | 1469 | 0.070 |
Why?
| | Intracranial Hypertension | 1 | 2007 | 36 | 0.070 |
Why?
| | Mice, SCID | 2 | 2019 | 312 | 0.070 |
Why?
| | Interferon-gamma | 1 | 2009 | 719 | 0.070 |
Why?
| | Thromboembolism | 1 | 2007 | 92 | 0.060 |
Why?
| | Flow Cytometry | 1 | 2009 | 1075 | 0.060 |
Why?
| | Emergency Treatment | 1 | 2007 | 113 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 211 | 0.060 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2007 | 127 | 0.060 |
Why?
| | Mice, Inbred NOD | 2 | 2019 | 552 | 0.060 |
Why?
| | Survival Rate | 2 | 2019 | 1638 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2008 | 445 | 0.060 |
Why?
| | Vasodilator Agents | 1 | 2007 | 302 | 0.060 |
Why?
| | Transplantation, Autologous | 1 | 2005 | 175 | 0.060 |
Why?
| | Syphilis, Cutaneous | 1 | 2004 | 2 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1690 | 0.060 |
Why?
| | Treponema pallidum | 1 | 2004 | 7 | 0.060 |
Why?
| | Anticoagulants | 1 | 2008 | 547 | 0.060 |
Why?
| | Anxiety Disorders | 1 | 2007 | 304 | 0.060 |
Why?
| | Cohort Studies | 2 | 2011 | 4885 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1078 | 0.050 |
Why?
| | Cytomegalovirus | 1 | 2023 | 143 | 0.050 |
Why?
| | Drug Interactions | 2 | 2013 | 337 | 0.050 |
Why?
| | Transplant Recipients | 1 | 2023 | 136 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2021 | 56 | 0.050 |
Why?
| | Sialic Acid Binding Ig-like Lectin 3 | 1 | 2021 | 8 | 0.050 |
Why?
| | Blood Grouping and Crossmatching | 1 | 2021 | 16 | 0.050 |
Why?
| | CD56 Antigen | 1 | 2021 | 34 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2007 | 2273 | 0.040 |
Why?
| | CD3 Complex | 1 | 2021 | 92 | 0.040 |
Why?
| | Ultrasonography | 3 | 2008 | 635 | 0.040 |
Why?
| | Phenylurea Compounds | 1 | 2020 | 81 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 2 | 2017 | 784 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2014 | 926 | 0.040 |
Why?
| | Clubfoot | 1 | 1999 | 10 | 0.040 |
Why?
| | Benzimidazoles | 1 | 2020 | 137 | 0.040 |
Why?
| | Lentivirus | 1 | 2019 | 45 | 0.040 |
Why?
| | Tarsal Bones | 1 | 1999 | 32 | 0.040 |
Why?
| | Machine Learning | 1 | 2022 | 315 | 0.040 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 10 | 0.040 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 15 | 0.040 |
Why?
| | Calcaneus | 1 | 1999 | 57 | 0.040 |
Why?
| | Electron Transport Complex II | 1 | 2018 | 23 | 0.040 |
Why?
| | Succinate Dehydrogenase | 1 | 2018 | 42 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 241 | 0.040 |
Why?
| | Tendons | 1 | 1999 | 118 | 0.040 |
Why?
| | Acetazolamide | 2 | 2008 | 30 | 0.040 |
Why?
| | Oxidative Phosphorylation | 1 | 2018 | 154 | 0.040 |
Why?
| | Genetic Testing | 1 | 2019 | 381 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 1999 | 206 | 0.030 |
Why?
| | NADP | 1 | 2016 | 42 | 0.030 |
Why?
| | Deoxyglucose | 1 | 2016 | 43 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 949 | 0.030 |
Why?
| | Prospective Studies | 2 | 2020 | 6198 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2017 | 292 | 0.030 |
Why?
| | Nitriles | 1 | 2017 | 149 | 0.030 |
Why?
| | Sesquiterpenes | 1 | 2016 | 51 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2014 | 3862 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 260 | 0.030 |
Why?
| | Cell Fusion | 1 | 2015 | 50 | 0.030 |
Why?
| | Severity of Illness Index | 3 | 2007 | 2540 | 0.030 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 134 | 0.030 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2014 | 14 | 0.030 |
Why?
| | Animals | 4 | 2019 | 31570 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2015 | 266 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 308 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 283 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 373 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1791 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 383 | 0.030 |
Why?
| | Pyrimidines | 1 | 2017 | 374 | 0.030 |
Why?
| | Cell Lineage | 1 | 2015 | 308 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2018 | 727 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2014 | 116 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 802 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2014 | 237 | 0.030 |
Why?
| | Philadelphia Chromosome | 1 | 2013 | 15 | 0.030 |
Why?
| | Survivors | 1 | 2016 | 415 | 0.030 |
Why?
| | Hospitalization | 2 | 2014 | 1763 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 341 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1024 | 0.020 |
Why?
| | Gene Expression | 1 | 2017 | 1417 | 0.020 |
Why?
| | Blood Transfusion | 1 | 2014 | 265 | 0.020 |
Why?
| | Probability | 1 | 2012 | 286 | 0.020 |
Why?
| | Cryopreservation | 1 | 2012 | 92 | 0.020 |
Why?
| | Mice | 2 | 2019 | 14847 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1131 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2011 | 137 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2015 | 1947 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2011 | 221 | 0.020 |
Why?
| | Disease Progression | 1 | 2017 | 2371 | 0.020 |
Why?
| | Viral Load | 1 | 2011 | 405 | 0.020 |
Why?
| | Apoptosis | 1 | 2018 | 2349 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2013 | 393 | 0.020 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2008 | 17 | 0.020 |
Why?
| | Donor Selection | 1 | 2009 | 65 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 2563 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 1824 | 0.020 |
Why?
| | Travel | 1 | 2008 | 121 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2014 | 2764 | 0.020 |
Why?
| | Gangrene | 1 | 2007 | 6 | 0.020 |
Why?
| | Bed Rest | 1 | 2007 | 15 | 0.020 |
Why?
| | Nifedipine | 1 | 2007 | 29 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2007 | 41 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2007 | 57 | 0.020 |
Why?
| | Iliac Artery | 1 | 2007 | 44 | 0.020 |
Why?
| | Albuterol | 1 | 2007 | 102 | 0.020 |
Why?
| | Linear Models | 1 | 2008 | 768 | 0.020 |
Why?
| | Sulfones | 1 | 2007 | 97 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2008 | 587 | 0.020 |
Why?
| | Purines | 1 | 2007 | 158 | 0.020 |
Why?
| | Femoral Artery | 1 | 2007 | 165 | 0.020 |
Why?
| | Reference Values | 1 | 2007 | 739 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 4682 | 0.020 |
Why?
| | Heart Rate | 1 | 2008 | 710 | 0.020 |
Why?
| | Leg | 1 | 2007 | 224 | 0.020 |
Why?
| | Piperazines | 1 | 2007 | 310 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 1830 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2004 | 180 | 0.010 |
Why?
| | Radiography, Thoracic | 1 | 2004 | 150 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1331 | 0.010 |
Why?
| | Disopyramide | 1 | 1981 | 1 | 0.010 |
Why?
| | Time Factors | 1 | 2011 | 6077 | 0.010 |
Why?
| | Heart Block | 1 | 1981 | 39 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1624 | 0.010 |
Why?
| | Israel | 1 | 1999 | 40 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1999 | 167 | 0.010 |
Why?
| | HIV Infections | 1 | 2012 | 2453 | 0.010 |
Why?
| | Pyridines | 1 | 1981 | 419 | 0.010 |
Why?
| | Reoperation | 1 | 1999 | 513 | 0.010 |
Why?
| | Radiography | 1 | 1999 | 803 | 0.010 |
Why?
| | Bundle-Branch Block | 1 | 1981 | 28 | 0.000 |
Why?
| | Heart Conduction System | 1 | 1981 | 80 | 0.000 |
Why?
|
|
Gutman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|